Detection of both Type 1 and Type 2 Plasminogen Activator Inhibitors in Human Monocytes

Summary

Increasing evidence suggests the involvement of leukocytes in the fibrinolytic system. Monocytes secrete pro-urokinase (Grau, Thromb Res 1989; 53: 145) and it has been shown that these cells have specific receptors for urokinase and plasminogen (Miles, Thromb Haemostas 1987; 58: 936). The aim of this study was to analyse the presence of plasminogen activator inhibitor(s) in platelet-free suspensions of human peripheral blood monocytes and polymorphonuclear leukocytes (PMN). SDS-PAGE and reverse fibrin autography showed an inhibitory band of 50 kDa in the monocyte extracts (Triton X-100) but not in the PMN extracts. Urokinase (u-PA) was mixed with increasing amounts of monocyte extract for 10 min and the mixtures were added to 125Ifibrin coated wells containing plasminogen. A dose-dependent decrease in the u-PA fibrinolytic activity was observed. The amount of inhibition increased when the monocyte releasates were preincubated with u-PA (40% inhibition after 5 min preincubation and 80% after 15 min), indicating a direct interaction between this activator and an inhibitor(s). After SDS-PAGE of monocyte extracts, immunoblotting and peroxidase staining identified both PAI1 and PAI2, with an apparent molecular weight of 47-50 kDa. Monocyte-associated PAI1 formed complexes with single chain t-PA with a molecular mass 50 kDa higher than the molecular mass of the free PAI1. However, a significant amount of PAI remained unbound to t-PA. This inactive PAI1 could have come from a rapid inactivation of the primary active PAI1. These PAI1 and PAI2 detected in human monocytes may be transcendent in the regulation of the fibrinolytic system.

Keywords

Fibrinolysis - Plasminogen activator inhibitor - Monocytes - Polymorphonuclear leukocytes - Immunoblotting

• References

• 1 Collen D. On the regulation and control of fibrinolysis. Thromb Haemostas 1980; 43: 77-89
• 2 Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-387
• 3 Erickson LA, Hekman CM, Loskutoff DJ. The primary plasmino-gen-activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related. Proc Natl Acad Sci USA 1985; 82: 8710-8714
• 4 Astedt B, Lecander I, Ny T. The placental type plasminogen activator inhibitor, PAI2. Fibrinolysis 1987; 1: 203-208
• 5 Johnston RB. Monocytes and macrophages. N Engl J Med 1988; 318: 747-752
• 6 Rivers RP A, Hathaway WE, Weston WL. The endotoxin-induced coagulant activity of human monocytes. Br J Haematol 1975; 30: 311-316
• 7 Edwards RL, Rickies FR, Bobrove AM. Mononuclear cell tissue factor: cell of origin and requirements for activation. Blood 1979; 54: 359-370
• 8 Broze GJ. Binding of human factor VII and Vila to monocytes. J Clin Invest 1982; 70: 526-535
• 9 Colvin RB, Dvorak HF. Fibrinogen/fibrin on the surface of macrophages, detection, distribution, binding requirements and possible role in macrophage adherence phenomena. J Exp Med 1975; 142: 1377-1390
• 10 Alitalo K, Hovi T, Vaheri A. Fibronectin is produced by human macrophages. J Exp Med 1980; 151: 602-613
• 11 Jaffe EA, Ruggiero JT, Falcone DJ. Monocytes and macrophages synthesize and secrete thrombospondin. Blood 1985; 65: 79-84
• 12 Grau E, Moroz LA. Fibrinolytic activity of normal human blood monocytes. Thromb Res 1989; 53: 145-162
• 13 Miles LA, Plow EF. Receptor mediated binding of the fibrinolytic components, plasminogen and urokinase, to peripheral blood cells. Thromb Haemostas 1987; 58: 936-942
• 14 Vassalli JD, Baccino D, Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 1985; 100: 86-92
• 15 Hunter WM, Greenwood FC. Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature (London) 1962; 194: 495-496
• 16 Recalde HR. A simple method of obtaining monocytes in suspension. J Immunol Methods 1984; 69: 71-77
• 17 Moroz LA. Increased blood fibrinolytic activity after aspirin ingestion. N Engl J Med 1977; 296: 525-529
• 18 Unkeless JC, Tobia A, Ossowski L, Quigley JP, Rifkin DB, Reich E. An enzymatic function associated with transformation of fibroblasts by oncogenic viruses. I. Chick embryo fibroblast cultures transformed by avian RNA tumor viruses. J Exp Med 1973 137. 85-111
• 19 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 277: 680-685
• 20 Erickson LA, Lawrence DA, Loskutoff DJ. Reverse fibrin autography: a method to detect and partially characterize protease inhibitors after Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis. Anal Biochem 1984; 137: 454-463
• 21 Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350-4354
• 22 Plow EF. The major fibrinolytic proteases of human leukocytes. Biochim Biophys Acta 1980; 63: 47-56
• 23 Kruithof EK O, Vassalli JD, Schleuning WD, Mattaliano RJ, Bachmann F. Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937. J Biol Chem 1986; 261: 11207-11213
• 24 Wohlwend A, Belin D, Vassalli JD. Plasminogen activator-specific inhibitors produced by human monocytes/macrophages. J Exp Med 1987; 165: 320-339
• 25 Schleef RR, Wagner NV, Loskutoff DJ. Detection of both type 1 and type 2 plasminogen activator inhibitors in human cells. J Cell Physiol 1988; 134: 269-274
• 26 Levin EG, Santell L. Conversion of the active to latent plasminogen activator inhibitor from human endothelial cells. Blood 1987; 70: 1090-1098